Table 4.
Comparison of subgroups according to cause of anti-PD-1 discontinuation in the anti-PD-1 cohort, University Hospital of Bordeaux, 2019.
| All patients, n = 65 | CR group, n = 25 | PR/SD group, n = 12 | AEs group, n = 28 | p value1 | |
|---|---|---|---|---|---|
| Median follow-up after introduction of treatment months (range) | 36.5 (4.6–62.4) | 40.5 (21–54.3) | 40.4 (25.4–62.4) | 29.7 (4.6–52.1) | 0.015 |
| Median TOT months (range) | 14.1 (0.7–51.2) | 16.8 (7.6–34.9) | 21.2 (10.1–51.2) | 7.2 (0.7–30.2) | <0.001 |
| Median follow-up after discontinuation months (range) | 15.7 (2.5–45.1) | 22.3 (6.2–42.3) | 11.3 (5.9–31.5) | 12.7 (2.5–45.1) | 0.144 |
| Median time to best response months (range) | 5.6 (0.7–32) | 6.2 (2.5–21.4) | 4.9 (2.8–27.8) | 4.5 (0.7–32) | 0.537 |
| Relapses, n (%) | 12 (18.5) | 3 (12) | 2 (16.7) | 7 (25) | 0.491 |
| Median time before relapse months (range) | 9 (1.9–40.9) | 9.3 (4–11.8) | 11.9 (10.9–12.8) | 7.1 (1.9–40.9) | 0.308 |
| Second-course after relapse, n (%) | 9 (13.8) | 3 (12) | 2 (16.7) | 4 (14.3) | 1 |
1 p value obtained with Kruskal–Wallis and Fisher tests for three groups equality. Abbreviation: TOT: time on treatment; CR, complete response; PR, partial response; SD, stable disease.